Teva Pharmaceutical Industries Limited Ordinary Shares (NY:TEVA)

39.25 +0.07 (+0.18%)

Official Closing Price Updated: 7:00 PM EDT, Oct 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Teva Pharmaceutical Industries Limited Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Teva Pharmaceutical (NYSE:TEVA) Nears Breakout With Perfect Technical Rating and Bull Flag Setup ↗

October 01, 2026

Via Chartmill

Teva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaround ↗

September 29, 2026

Built on substance, not hype, Teva's mega rally is just getting started.

Via The Motley Fool

Teva Eyes New Growth Phase After Securing Investment-Grade Ratings ↗

September 23, 2026

Teva Pharmaceutical Industries (NYSE:TEVA) is planning for greater financial flexibility after receiving investment-grade ratings from all three major credit rating agencies, President and CEO Richard...

Via MarketBeat

Topics Bankruptcy

Teva CEO Details Biopharma Pivot, $700M Savings Plan and Growth Pipeline ↗

September 22, 2026

Teva Pharmaceutical Industries (NYSE:TEVA) Chief Executive Officer Richard Francis said the company has shifted from being viewed primarily as a generics manufacturer toward a biopharmaceutical company...

Via MarketBeat

TEVA PHARMACEUTICAL-SP ADR (NYSE:TEVA) Flags Technical Breakout Setup with Top Ratings ↗

May 30, 2026

Via Chartmill

Teva Says Pivot to Growth Gains Steam as Branded Drugs, Biosimilars Outperform ↗

September 14, 2026

Teva Pharmaceutical Industries (NYSE:TEVA) CEO Richard Francis said the company has progressed from the initial phase of its “Pivot to Growth” plan into its next stage, citing momentum in branded...

Via MarketBeat

Topics World Trade

Teva Pharmaceuticals Sees Pivot to Growth Accelerating on Branded Drugs, Biosimilars ↗

September 14, 2026

Teva Pharmaceutical Industries (NYSE:TEVA) said its “Pivot to Growth” strategy has moved into its second phase, with management pointing to momentum in branded medicines, a stabilized generics...

Via MarketBeat

Teva’s TEV-408 Hits Key Phase IIa Endpoint in Celiac Disease Study ↗

September 02, 2026

Teva Pharmaceutical Industries (NYSE:TEVA) reported positive topline results from a Phase IIa gluten-challenge study of TEV-408, its anti-IL-15 antibody candidate for celiac disease, with the company...

Via MarketBeat

Teva (TEVA) Q2 2026 Earnings Call Transcript ↗

August 07, 2026

Key innovative brands now generate over $1B quarterly revenue.

Via The Motley Fool

Topics Earnings

Why Teva Pharmaceutical Stock Surged This Week ↗

August 02, 2026

Teva reported its Q2 results this week, but the stock's big gains mostly stemmed from another catalyst.

Via The Motley Fool

Topics Stocks

Teva Pharmaceutical Industries Q2 Earnings Call Highlights ↗

July 30, 2026

Teva Pharmaceutical Industries (NYSE:TEVA) reported second-quarter 2026 revenue of approximately $4.1 billion, down 1% from a year earlier in U.S. dollars, as lower sales from generic Revlimid were...

Via MarketBeat

Topics Earnings

Teva's Turnaround Is Working. Here's the 1 Thing That Could Send It Soaring Another 50%. ↗

July 26, 2026

The pharmaceutical company has a likely blockbuster drug as the flagship of its pipeline.

Via The Motley Fool

Wall Street Thinks Teva Can Soar Over 60%. Here's Why Analysts Are Right. ↗

July 26, 2026

The stock has a 100% buy rating from polled analysts, with some eye-catching price targets.

Via The Motley Fool

Topics Intellectual Property

Teva Pharmaceutical Industries’ Anti-IL-15 Antibody Shows Promise in Vitiligo Study ↗

July 12, 2026

Teva Pharmaceutical Industries (NYSE:TEVA) said its internally developed anti-IL-15 antibody produced encouraging 24-week efficacy results in a phase 1b proof-of-concept study for vitiligo, as the...

Via MarketBeat

Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? ↗

July 09, 2026

Novartis boasts a 26% net margin and a fortress balance sheet, while Teva's turnaround has returned it to profitability, but at what cost to stability?

Via The Motley Fool

Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? ↗

July 06, 2026

Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt reduction and biosimilar expansion.

Via The Motley Fool

Teva Just Delivered More Good News on Its Biggest Growth Driver. Is the Stock Still a Bargain? ↗

June 19, 2026

Teva has been building its comeback, and the latest studies on Austedo and Austedo XR will help further that momentum.

Via The Motley Fool

June 12, 2026

Driving revenue growth and earnings growth are two different things.

Via The Motley Fool

Topics Intellectual Property

Teva Pharmaceutical Industries Just Pulled Off One of Pharma's Most Impressive Comebacks ↗

June 01, 2026

Teva's transformation is gaining momentum.

Via The Motley Fool

Teva Stock Is at Its Highest Level in Nearly a Decade. Here's Why It Could Soar Even More. ↗

May 15, 2026

The market's rediscovery of Teva Pharmaceuticals remains ongoing.

Via The Motley Fool

Wall Street Thinks Teva Stock Still Has Room to Run After Soaring Over 100%. Here's Why Analysts Are Right. ↗

May 14, 2026

Teva's turnaround is real -- and may not be over.

Via The Motley Fool

Blackstone's $400 Million Bet on Teva: What Does the Smart Money Know That Most Investors Don't? ↗

April 30, 2026

A significant financing deal with Blackstone underscores that the Teva of today isn't the Teva of the past.

Via The Motley Fool

Teva Pharmaceutical's Turnaround Is Working. Here's When to Buy the Stock. ↗

April 27, 2026

That's when its first-quarter results will be published.

Via The Motley Fool

3 Catalysts That Could Send Teva Stock to $40 and Beyond ↗

April 18, 2026

This once-beaten-down pharma stock remains an intriguing turnaround story.

Via The Motley Fool

Neurocrine Biosciences (NBIX): A New Era in Neuroscience and Endocrinology

April 07, 2026

Date: April 7, 2026 Introduction Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has long been a bellwether for the mid-cap biotechnology sector, serving as a primary case study in how a company can...

Via Finterra

Topics Earnings Economy Intellectual Property

Corcept Therapeutics Outperforms: How a Surprise FDA Approval Ignited a Late-March Rally

March 31, 2026

In a month characterized by macroeconomic headwinds and a broader cooling of the biotechnology sector, Corcept Therapeutics (NASDAQ: CORT) has emerged as a definitive outlier. While the S&P Biotech ETF...

Via MarketMinute

Topics ETFs Intellectual Property Stocks

MarketMinute: Corcept Therapeutics (CORT) Surges 19.66% on Surprise FDA Approval and Oncology Breakthrough

March 26, 2026

The biotechnology sector witnessed a seismic shift on March 26, 2026, as shares of Corcept Therapeutics (NASDAQ: CORT) surged 19.66% in heavy trading. The rally, which added nearly $1 billion to the...

Via MarketMinute

Topics Intellectual Property

The Second Act: A Deep-Dive into Corcept Therapeutics and the FDA Approval of Lifyorli

March 26, 2026

March 26, 2026 Introduction Yesterday, March 25, 2026, Corcept Therapeutics (NASDAQ: CORT) reached a defining milestone that has fundamentally altered its investment profile: the early FDA approval of...

Via Finterra

Topics Economy Intellectual Property

This $7 Million Masimo Exit Came Before a 34% Surge on $9.9 Billion Acquisition ↗

March 22, 2026

Masimo develops advanced noninvasive monitoring technologies used by hospitals and healthcare providers worldwide.

Via The Motley Fool

The $1.3 Trillion Architect: How Blackstone is Redefining Global Finance through Private Credit and Essential Consumerism

March 18, 2026

By Finterra Editorial TeamMarch 18, 2026 Introduction In the high-stakes world of global alternative asset management, one name looms larger than the rest: Blackstone Inc. (NYSE: BX). As of March 18,...

Via Finterra

Topics Artificial Intelligence Economy Energy

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.